likely to have VWINGS in use at last follow-up (P < .007). No differences in use were found between clinic providers. A total of 77 (12%) patients had at least one device removed. Reasons for explantation were 28.6% infection, 26% cannulation difficulties, 11.7% device moved, 11.7% no longer needed, 6.5% excessive scarring, and 15.6% unknown. A total of 44 patients (6.7%) had a secondary procedure, not including catheter placement. There were no known fistula failures due to device placement or removal. Fistula survival was 87%. Failure of 84 fistulas (12.8%) occurred an average of 254 days after implantation.
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Outcomes of Forearm Loop Grafts and the
Objectives: Preservation of potential hemodialysis (HD) access sites is an emphasis of current guidelines as patients may experience multiple access failures during their lifetime. When forearm vein is inadequate for radiocephalic arteriovenous fistula (AVF) creation, current guidelines favor upper arm AVF, but this approach may sacrifice potential HD access sites. We hypothesized that forearm loop grafts (fAVG) have acceptable patency and create additional access sites by dilating the upper arm basilic and cephalic vein.
Methods: We retrospectively reviewed all HD access procedures at a single academic institution from September 2009 to December 2015. Outcomes of fAVG were compared with upper arm AVF. Forearm AVFs and upper arm AVGs were excluded from the analysis. We compared primary and cumulative patency between the two co-cohorts. Forearm AVGs were evaluated with preoperative vein mapping to determine whether there was adequate upper arm cephalic and/or basilica vein at the time of graft insertion. Additionally, we evaluated patients with failed fAVG an increase in potential ipsilateral access sites after fAVG failure, defined as ipsilateral cephalic or basilic upper arm vein $3 mm by duplex vein mapping.
Results: Thirty-six fAVGs and 163 upper arm AVFs were created during the study period. In the fAVG cohort, 28 were inserted with ipsilateral cephalic and/or basilic upper arm vein <3 mm, and eight were inserted with ipsilateral upper arm vein $3 mm. Primary and cumulative patency of fAVG with $3 mm upper ipsilateral arm vein were similar to upper arm AVF (Table) . The primary and cumulative patency at 6 months and 1 year are noted in the Table. One-third (3 of 9) patients in the fAVG cohort with <3 mm cephalic and/or basilica vein experienced dilation of the upper arm ipsilateral cephalic and/or basilic veins to $3 mm after AVG failure. The average increase vein diameter was 0.7 6 1.3 mm. Reasons for not observing an increase of ipsilateral vein diameter after fAVG failure include <3 months of a patent forearm loop graft, stenting across the outflow vein across the elbow, and initial vein caliber <2 mm.
Conclusions Objectives: Thoracic endovascular aortic repair (TEVAR) has become the treatment of choice for aortic dissections in many centers. While adequate proximal seal is a fundamental requisite for TEVAR, there are insufficient data on the impact of the proximal seal length on patient outcomes. The goal of this study was to describe the proximal seal zone achieved during TEVAR for aortic dissections as well as its effect on clinical outcomes and aortic remodeling.
Methods: A retrospective review was performed on all patients who underwent TEVAR for aortic dissections at a single institution from 2006 to 2016. Preoperative computed tomography (CT) was used to identify the entry tear, extent of dissection, and distances between the arch branches in three-dimensional centerline. Proximal seal zone length was calculated on postoperative imaging. Sequential postoperative CT scans were analyzed for remodeling of the true and false lumen aortic diameters over time. Clinical outcomes, including retrograde type A dissection (RTAD), death, and aortic reinterventions, were recorded.
Results: During the study period, 84 patients underwent TEVAR for aortic dissections. Indications for TEVAR were malperfusion (n ¼ 12), aneurysm (n ¼ 26), persistent pain (n ¼ 33), rupture (n ¼ 8), uncontrolled hypertension (n ¼ 2), and other (n ¼ 3). Mean follow-up was 14 months (range, 0-94 months). In 28 patients (33%), the aorta proximal to stent graft was without intramural hematoma, while the proximal seal zone in 56 patients (67%) was entirely in intramural hematoma. Proximal seal according to the manufacturers' instructions for use (2 cm of normal aorta) was achieved in only six patients (7.1%). Thirty-nine patients (46%) would have required total arch debranching to obtain a 2-cm proximal seal. After TEVAR deployment in intramural hematoma, two RTADs underwent operative repair, and one patient had a sudden death. No RTADs occurred after TEVAR deployment in nondissected aorta without intramural hematoma. Overall reintervention-free survival was 52% at 24 months. Mean expansion of thoracic true lumen diameters were 151%, 177%, 191%, 202%, and 211% of baseline at the 1-, 6-, 12-, 24-, and 36-month follow-up, respectively. Regression of thoracic false lumen diameters was seen in 87%, 83%, 73%, 71%, and 70% at the 1-, 6-,12-, 24-, and 36-month follow-up. Complete thoracic false lumen thrombosis was seen in 55%. Aortic remodeling, such as false lumen thrombosis, true lumen expansion, and false lumen regression, was not different between the patients who had a proximal landing zone in the intramural hematoma and those who did not. Conclusions: Achieving a 2-cm proximal seal zone in TEVAR for aortic dissections often requires extensive arch debranching. Stent graft deployment with shorter than a 2-cm proximal seal zone in a normal aorta without intramural hematoma avoids RTAD, and induces aortic remodeling.
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Secondary Interventions After Fenestrated Endovascular Aneurysm Repair
Benjamin W. Starnes, Billi Tatum, Niten Singh. University of Washington, Seattle, Wash
Objectives: Type Ia endoleak represents failure of the primary mode of therapy to treat juxtarenal abdominal aortic aneurysm (jAAA) with endovascular means. Fenestrated endovascular aneurysm repair (FEVAR) is associated with low rates of type Ia endoleak and low rates of reintervention. In most modern series of standard EVAR, the rate of secondary intervention is between 3.8% and 37% (Nordon et al. Eur J Vasc Endovasc Surg 2010; 39:547-54) , and up to two-thirds of these are due to endoleak. Our objective was to characterize the incidence and types of secondary interventions in a modern series of FEVAR.
Methods: Patients with jAAA who were not candidates for open repair were enrolled into an investigational device exemption clinical trial (#NCT01538056) and treated with FEVAR. Clinical and imaging data were collected out to 5 years.
Results: A total of 92 patients were treated with FEVAR over the reporting period. There were 22 secondary interventions in 16 subjects (17.4%). Of these 22 interventions, 8 were access related (36%), 7 were branch related (32%), and 6 were related to endoleak (27%). One was both branch related and due to endoleak. There were one type II, one type Ib, and four type III endoleaks that required treatment. The rate of type Ia endoleak requiring secondary intervention was zero (0%). The overall rate of endoleak requiring intervention was 6.5%, and the incidence of branch vessel complication requiring intervention was seven of a total of 242 fenestrations (2.9%). All patients underwent an attempt at a completely percutaneous procedure (n ¼ 184), and 20 access devices failed (10.9%) requiring immediate surgical conversion and common femoral artery repair during the index operation. Of 184 vessels accessed for the procedure, eight (4.3%) required a secondary intervention after the index procedure. No patient in this series ruptured at any time with a mean of 22 months of follow-up.
Conclusions: These data compare favorably with all other reported FEVAR series. Access-related complications are infrequent but still the most common after FEVAR. When performed for appropriate indications, type Ia endoleaks are rare if not absent after FEVAR. It appears that secondary intervention for endoleak is much less common than in contemporary series of standard EVAR. Branch vessel patency after FEVAR is excellent. Objectives: Type Ia endoleak after previous endovascular aortic repair (EVAR) is a challenging pathologic process. Patients often experience symptoms requiring treatment in the urgent setting with also often coexisting anatomically demanding conditions with the migrated endograft in angulated and short necks. Aim of the study was to evaluate the repro- 
